Hercules Capital (HTGC) has fallen about 18% year-to-date, yet its portfolio remains strong, focused on healthcare and application software sectors with high barriers to entry and AI benefits. The company maintains excellent credit quality, with only 0.1% of its portfolio on non-accrual and a 12% yield, supporting a Strong Buy rating. Analysts expect HTGC to recover to its historical 1.5x NAV premium, targeting $17.85 per share and over 27% total return upside. This resilience and growth potential make HTGC a notable choice among business development companies (BDCs).
Halper Sadeh LLC is investigating whether the sales and merger deals involving AstroNova, Simulations Plus, and Olin Corporation provide fair treatment to their shareholders. The firm suspects insiders may gain financial benefits not available to ord...
Halper Sadeh LLC is investigating whether shareholders of Apogee Therapeutics, Open Lending, Huntsman, and Avanos Medical are receiving fair deals in their companies' recent sales. The law firm suspects insiders may gain financial benefits not availa...
CEA Industries and YZi Labs have reached a cooperation agreement to strengthen governance at CEA Industries, which manages the world's largest corporate treasury of BNB. The agreement includes appointing three new board members with digital asset exp...
China's LineShine supercomputer, built by the Shenzhen Cloud Computing Center, has become the world's fastest, overtaking the US's El Capitan. This marks the first time since 2017 that China holds the top spot, with LineShine performing 20% better on...
Former New York Governor Andrew Cuomo, now co-chair of a joint venture between fintech OKX and Intercontinental Exchange, advocates for blockchain technology to reduce costs and improve financial services by bypassing traditional banks. He highlights...
